Pharmacologic therapies for diabetic retinopathy and diabetic macular edema - Wikidata - awgldk - TriplyDB

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

http://www.wikidata.org/entity/Q33492340

about

High glucose alters Cx43 expression and gap junction intercellular communication in retinal Müller cells: promotes Müller cell and pericyte apoptosis.Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema.One year of Clinical Ophthalmology.Antagonizing Wnt pathway in diabetic retinopathy.

P2860

Q33901473-8D457948-BD9E-47EB-86F3-79611B7153B5 Q36856905-FA410992-25DE-4279-A536-0548D59D5BFA Q37038541-1C36470D-EFBB-4BDC-AD0A-5C17A38C067E Q42021819-01846383-526A-4404-B1A9-73CD44EA0955 Q42149497-71B672CB-4377-447F-AFDF-398924759556

P2860

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

http://www.wikidata.org/entity/Q33492340

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

@ast

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

@en

type

label

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

@ast

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

@en

prefLabel

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

@ast

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

@en

P1433

Q33492340-9BB64C94-BB63-4685-A66E-CCD8082BD92A

P1476

Q33492340-7E3A6ADA-B5B1-4C96-A11C-08329012BCC6

P2093

Q33492340-1E389AAE-328D-4204-8FFC-4BEE3522F42F

Q33492340-275A4634-7107-44E0-AD57-1D80FB5C4176

Q33492340-926FAF37-8126-4E23-BFBE-B9C3A9AE6A27

Q33492340-C5C846A5-A0F8-4BBA-A45E-19ACBDFBA88C

P2860

Q33492340-00955EF3-C7D2-4BA4-8DEE-0308C933F3A1

Q33492340-152B9304-8B4D-4D89-970B-057FCDAC7629

Q33492340-294BBDE8-79D3-4EE3-9E26-A0C82C32A5D3

Q33492340-31E28FA8-CA88-4CB3-B49B-3D7236588A0D

Q33492340-34312F66-E95E-4A2C-BCAE-B0C94A23A87E

Q33492340-36060EA2-9C33-4508-9F9D-B8B6A4BF76B5

Q33492340-3765EB7B-578C-42AC-A3E1-D62CD99351FE

Q33492340-393A2EFF-7031-4B85-A73E-27FE9492A8D0

Q33492340-3BF09E70-CF5E-4C98-9E15-9B502CA48D6C

Q33492340-3D524689-984B-4F37-8F4A-37D16FC7ACCC

P304

Q33492340-0735854B-9EB9-4082-AAB4-E1986B2007EC

P31

Q33492340-53DD5C33-5112-4581-A053-7C0C55B7FF33

P407

Q33492340-687717AA-F295-44D4-BA29-374829508B21

P433

Q33492340-A0DA8158-411A-4497-A70A-C65E3B565D5D

P478

Q33492340-93235F5B-8331-48B2-ACAC-A07510537B42

P577

Q33492340-1A68390F-B60E-4760-9554-404249E942D4

P698

Q33492340-489A4005-C2BE-414B-AF09-61D8CFFAE141

P932

Q33492340-BC0DAD32-A337-4CEA-87AB-840508D61510

P1433

Clinical Ophthalmology

P1476

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema

@en

P2093

Alon Harris

http://www.w3.org/2001/XMLSchema#string

Ehud Rechtman

http://www.w3.org/2001/XMLSchema#string

Hanna J Garzozi

http://www.w3.org/2001/XMLSchema#string

Thomas A Ciulla

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis.

Cost effectiveness of current approaches to the control of retinopathy in type I diabetics.

Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531.

P304

383-391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19668515

http://www.w3.org/2001/XMLSchema#string

P932

2704543

http://www.w3.org/2001/XMLSchema#string